Hematology

Articles

The combination of venetoclax and azacitidine will be considered as a treatment for patients with newly diagnosed, higher-risk myelodysplastic syndrome.

Venetoclax Combination Earns FDA Breakthrough Therapy Designation for Higher-Risk MDS

Data presented from the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials at 2021 EHA indicate success of momelotinib in extending overall survival in patients with myelofibrosis who achieve transfusion independence.


Improved OS Seen With Momelotinib-Associated Transfusion Independence at 24 Weeks in Myelofibrosis

A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Data from initial dose cohorts of a phase 1/2 trial indicated the agent was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.

GTB-3550 TriKE Safely Drives NK Cell Function in MDS, AML

The FDA granted breakthrough therapy designation to magrolimab for the treatment of newly diagnosed myelodysplastic syndrome.

FDA Grants Breakthrough Therapy Designation to Magrolimab for Treatment of MDS

The study evaluated the efficacy and safety of IV rigosertib in patients with high-risk MDS who had progressed on, failed to respond to, or relapsed after previous treatment with an HMA within 9 cycles over the course of 1 year after initiation of HMA treatment.

Phase 3 INSPIRE Study Fails to Meet Primary End Point of Improved Survival 

Takeda Pharmaceutical Company Limited announced the FDA granted pevonedistat, its investigation NEDD8-activating enzyme inhibitor, breakthrough therapy designation to treat patients with higher-risk myelodysplastic syndrome.

FDA Grants Breakthrough Therapy Designation for Pevonedistat to Treat Higher-Risk MDS

The FDA has approved an oral combination of decitabine and cedazuridine for adult patients with myelodysplastic syndromes.

FDA Approves Oral Combo of Decitabine and Cedazuridine for Myelodysplastic Syndromes

The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS

The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions.

Myelodysplastic Syndromes | Topics